PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsDabigatran
Dabigatran
Dabigatran Etexilate, Pradaxa (dabigatran) is a small molecule pharmaceutical. Dabigatran was first approved as Pradaxa on 2008-03-17. It has been approved in Europe to treat replacement arthroplasty and venous thromboembolism. The pharmaceutical is active against prothrombin.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
operative surgical proceduresD013514
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name
Status
Last Update
dabigatranANDA2025-04-09
dabigatran etexilateANDA2025-05-15
pradaxaNew Drug Application2024-04-03
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
Expiration
Code
DABIGATRAN ETEXILATE MESYLATE, PRADAXA, BOEHRINGER INGELHEIM
2024-12-21PED
2024-06-21I-862, NP
Patent Expiration
Patent
Expires
Flag
FDA Information
Dabigatran Etexilate Mesylate, Pradaxa, Boehringer Ingelheim
90348222031-01-20U-1759
79322732025-09-07DS, DP
ATC Codes
B: Blood and blood forming organ drugs
B01: Antithrombotic agents
B01A: Antithrombotic agents
B01AE: Direct thrombin inhibitors
B01AE07: Dabigatran etexilate
HCPCS
No data
Clinical
Clinical Trials
420 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Atrial fibrillationD001281EFO_0000275I48.043132747
ThromboembolismD0139239113831
Venous thromboembolismD054556EFO_0004286I74881522
ThrombosisD01392721216
Renal insufficiencyD051437N19325
Replacement arthroplastyD019643134
Cognitive dysfunctionD060825G31.84123
Heart valve diseasesD006349EFO_0009551I08112
Coronary artery diseaseD003324I25.1112
Myocardial ischemiaD017202EFO_1001375I20-I25112
Show 9 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
HemorrhageD006470MP_0001914R581438
StrokeD020521EFO_0000712I63.91225
Replacement arthroplasty kneeD019645123
Secondary preventionD05550222
Neoplasm metastasisD009362EFO_000970822
Replacement arthroplasty hipD019644112
HematomaD006406EFO_001068011
Embolic strokeD00008326211
Percutaneous coronary interventionD06264511
Intracranial sinus thrombosisD01285111
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Coronary diseaseD003327112
Acute coronary syndromeD054058EFO_000567211
Cardiac catheterizationD00632811
Heart valve prosthesisD006350EFO_000390611
Venous thrombosisD020246I82.4011
Indications Without Phase
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDabigatran
INNdabigatran
Description
Dabigatran is an aromatic amide obtained by formal condensation of the carboxy group of 2-{[(4-carbamimidoylphenyl)amino]methyl}-1-methyl-1H-benzimidazole-5-carboxylic acid with the secondary amoino group of N-pyridin-2-yl-beta-alanine. The active metabolite of the prodrug dabigatran etexilate, it acts as an anticoagulant which is used for the prevention of stroke and systemic embolism. It has a role as an anticoagulant, an EC 3.4.21.5 (thrombin) inhibitor and an EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor. It is an aromatic amide, a member of benzimidazoles, a carboxamidine, a member of pyridines and a beta-alanine derivative.
Classification
Small molecule
Drug classthrombin inhibitors (argatroban type)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Cn1c(CNc2ccc(C(=N)N)cc2)nc2cc(C(=O)N(CCC(=O)O)c3ccccn3)ccc21
Identifiers
PDB
CAS-ID211914-51-1
RxCUI
ChEMBL IDCHEMBL48361
ChEBI ID70752
PubChem CID216210
DrugBankDB14726
UNII IDI0VM4M70GC (ChemIDplus, GSRS)
Target
Agency Approved
F2
F2
Organism
Homo sapiens
Gene name
F2
Gene synonyms
NCBI Gene ID
Protein name
prothrombin
Protein synonyms
Coagulation factor II, prepro-coagulation factor II, prothrombin B-chain, thrombin factor II
Uniprot ID
Mouse ortholog
F2 (14061)
prothrombin (P19221)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
£
No data
Estimated US medical usage
Dabigatran
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 16,055 documents
View more details
Safety
Black-box Warning
Black-box warning for: Dabigatran, Dabigatran etexilate, Pradaxa
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
78,971 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use